This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Crux Biomedical Names Randy Lindholm Chairman Of Its Board Of Directors

Stocks in this article: OMCL

MENLO PARK, Calif., Sept. 28, 2011 /PRNewswire/ -- Crux Biomedical, developer of an advanced implantable vena cava filter (IVCF) to prevent pulmonary embolisms, announced the appointment of Randy Lindholm as the Company's Chairman of the Board. Mr. Lindholm has served on the Company's Board of Directors since March 2011.

Mr. Lindholm was previously Chairman of the Board and CEO of Vidamed, a maker of minimally invasive medical devices to treat benign prostate hyperplasia until it was acquired by Medtronic. Prior to Vidamed, Randy held senior positions at GE Medical Systems and Nellcor Puritan Bennett. "I am excited to assume this expanded role at Crux Biomedical. The company is well positioned to take advantage of the current high level of interest in a better performing, retrievable IVC filter," stated Mr. Lindholm. He has served on numerous medical device company boards, and currently serves as director of publically held Omnicell (Nasdaq: OMCL), as well as privately held Barrx Medical, Tibion Bionic Technologies, Novasys Medical, and Estech.

"We are very pleased to have Randy's strategic experience here at Crux, now as Chairman of the Board," states Mel Schatz, CEO of Crux Biomedical. He continued, "Randy has been very helpful in the past assisting numerous firms to best optimize their growth and strategic alternatives."

Crux Biomedical has completed enrolling patients in its pivotal IDE study in the United States. The Company expects to launch internationally in early 2012. "Now that patient enrollment has been completed, it is the right time to elevate Randy to the Chairman role to continue the momentum that Crux has created," noted Doug Kelly, M.D., General Partner at Alloy Ventures, and majority shareholder of Crux Biomedical.

Crux Biomedical was founded in 2004 by Thomas Fogarty, M.D., to target the development of an advanced implantable inferior vena cava filter (IVCF) to prevent the occurrence of potentially fatal pulmonary embolisms. Although routinely used in the United States, currently cleared IVC filters are associated with a variety of complications. "We recognized current IVC filters did not meet the needs of clinicians and designed a filter that provided better retrievability," stated Tom Fogarty, M.D.

Each year in the United States approximately 600,000 patients develop a PE and an estimated 200,000 deaths occur. Pulmonary embolisms are recognized as the most preventable cause of death among hospitalized patients.

Crux Biomedical is located in Menlo Park, California and is funded by Alloy Ventures, Emergent Medical Partners, and Three Arch Partners.

SOURCE Crux Biomedical

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs